Prevalence of cardiac comorbidities, and their underdetection and contribution to exertional symptoms in COPD: results from the COSYCONET cohort

References

• Vanfleteren LE, Spruit MA, Groenen M, et al. Clusters of comorbidities based on validated objective measurements and systemic inflammation in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2013;187(7):728–735. doi:10.1164/rccm.201209-1665OC23392440
   PubMed Web of Science ®Google Scholar
• Mullerova H, Agusti A, Erqou S, Mapel DW. Cardiovascular comorbidity in COPD: systematic literature review. Chest. 2013;144(4):1163–1178. doi:10.1378/chest.12-284723722528
   PubMed Web of Science ®Google Scholar
• Gershon AS, Mecredy GC, Guan J, Victor JC, Goldstein R, To T. Quantifying comorbidity in individuals with COPD: a population study. Eur Respir J. 2015;45(1):51–59. doi:10.1183/09031936.0006141425142481
   PubMed Web of Science ®Google Scholar
• Greulich T, Weist BJD, Koczulla AR, et al. Prevalence of comorbidities in COPD patients by disease severity in a German population. Respir Med. 2017;132:132–138.29229085
   PubMed Web of Science ®Google Scholar
• Triest FJ, Franssen FM, Spruit MA, Groenen MT, Wouters EF, Vanfleteren LE. Poor agreement between chart-based and objectively identified comorbidities of COPD. Eur Respir J. 2015;46(5):1492–1495.26341984
   PubMed Web of Science ®Google Scholar
• Miller J, Edwards LD, Agusti A, et al. Comorbidity, systemic inflammation and outcomes in the ECLIPSE cohort. Respir Med. 2013;107(9):1376–1384.23791463
   PubMed Web of Science ®Google Scholar
• Stone IS, Barnes NC, James WY, et al. Lung deflation and cardiovascular structure and function in chronic obstructive pulmonary disease. A randomized controlled trial. Am J Respir Crit Care Med. 2016;193(7):717–726.26550687
   PubMed Web of Science ®Google Scholar
• Alter P, Jorres RA, Watz H, et al. Left ventricular volume and wall stress are linked to lung function impairment in COPD. Int J Cardiol. 2018;261:172–178.29657040
   PubMed Web of Science ®Google Scholar
• Alter P, Watz H, Kahnert K, et al. Airway obstruction and lung hyperinflation in COPD are linked to an impaired left ventricular diastolic filling. Respir Med. 2018;137:14–22.29605197
   PubMed Web of Science ®Google Scholar
• Hohlfeld JM, Vogel-Claussen J, Biller H, et al. Effect of lung deflation with indacaterol plus glycopyrronium on ventricular filling in patients with hyperinflation and COPD (CLAIM): a double-blind, randomised, crossover, placebo-controlled, single-centre trial. Lancet Respir Med. 2018;6(5):368–378. doi:10.1016/S2213-2600(18)30054-729477448
   PubMed Web of Science ®Google Scholar
• Hawkins NM, Huang Z, Pieper KS, et al. Chronic obstructive pulmonary disease is an independent predictor of death but not atherosclerotic events in patients with myocardial infarction: analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT). Eur J Heart Fail. 2009;11(3):292–298. doi:10.1093/eurjhf/hfp00119176539
   PubMed Web of Science ®Google Scholar
• Iversen KK, Kjaergaard J, Akkan D, et al. The prognostic importance of lung function in patients admitted with heart failure. Eur J Heart Fail. 2010;12(7):685–691. doi:10.1093/eurjhf/hfq05020395261
   PubMed Web of Science ®Google Scholar
• Lawson CA, Mamas MA, Jones PW, et al. Association of medication intensity and stages of airflow limitation with the risk of hospitalization or death in patients with heart failure and chronic obstructive pulmonary disease. JAMA Network Open. 2018;1(8):e185489. doi:10.1001/jamanetworkopen.2018.548930646293
   PubMed Web of Science ®Google Scholar
• Sato Y, Yoshihisa A, Oikawa M, et al. Prognostic impact of chronic obstructive pulmonary disease on adverse prognosis in hospitalized heart failure patients with preserved ejection fraction - A report from the JASPER registry. J Cardiol. 2019;73(6):459–465. doi:10.1016/j.jjcc.2019.01.00530718015
   PubMed Web of Science ®Google Scholar
• Lucke T, Herrera R, Wacker M, et al. Systematic analysis of self-reported comorbidities in large cohort studies - a novel stepwise approach by evaluation of medication. PLoS One. 2016;11(10):e0163408. doi:10.1371/journal.pone.016340827792735
   PubMed Web of Science ®Google Scholar
• Graf J, Lucke T, Herrera R, et al. Compatibility of medication with PRISCUS criteria and identification of drug interactions in a large cohort of patients with COPD. Pulm Pharmacol Ther. 2018;49:123–129. doi:10.1016/j.pupt.2018.01.01129421666
   PubMed Web of Science ®Google Scholar
• Karch A, Vogelmeier C, Welte T, et al. The German COPD cohort COSYCONET: aims, methods and descriptive analysis of the study population at baseline. Respir Med. 2016;114:27–37. doi:10.1016/j.rmed.2016.03.00827109808
   PubMed Web of Science ®Google Scholar
• Vogelmeier CF, Criner GJ, Martinez FJ, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report. GOLD executive summary. Am J Respir Crit Care Med. 2017;195(5):557–582. doi:10.1164/rccm.201701-0218PP28128970
   PubMed Web of Science ®Google Scholar
• Celli BR, Decramer M, Wedzicha JA, et al. An Official American Thoracic Society/European Respiratory Society Statement: research questions in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2015;191(7):e4–e27. doi:10.1164/rccm.201501-0044ST25830527
   PubMed Web of Science ®Google Scholar
• Vogelmeier C, Buhl R, Criee CP, et al. [Guidelines for the diagnosis and therapy of COPD issued by Deutsche Atemwegsliga and Deutsche Gesellschaft fur Pneumologie und Beatmungsmedizin]. Pneumologie. 2007;61(5):e1–e40. doi:10.1055/s-2007-95920017436190
   PubMedGoogle Scholar
• Criee CP, Sorichter S, Smith HJ, et al. Body plethysmography–its principles and clinical use. Respir Med. 2011;105(7):959–971. doi:10.1016/j.rmed.2011.02.00621356587
   PubMed Web of Science ®Google Scholar
• Criee CP, Baur X, Berdel D, et al. [Standardization of spirometry: 2015 update. Published by German Atemwegsliga, German Respiratory Society and German Society of Occupational and Environmental Medicine]. Pneumologie. 2015;69(3):147–164. doi:10.1055/s-0034-139134525750095
   PubMedGoogle Scholar
• Vogelmeier C, Buhl R, Burghuber O, et al. [Guideline for the diagnosis and treatment of COPD patients - issued by the German Respiratory Society and the German Atemwegsliga in Cooperation with the Austrian Society of Pneumology]. Pneumologie. 2018;72(4):253–308. doi:10.1055/s-0043-12503129523017
   PubMed Web of Science ®Google Scholar
• Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault JC. Lung volumes and forced ventilatory flows. Eur Respir J. 1993;6(Suppl 16):5–40. doi:10.1183/09041950.005s1693
   PubMed Web of Science ®Google Scholar
• Quanjer PH, Stanojevic S, Cole TJ, et al. Multi-ethnic reference values for spirometry for the 3-95-yr age range: the global lung function 2012 equations. Eur Respir J. 2012;40(6):1324–1343. doi:10.1183/09031936.0008031222743675
   PubMed Web of Science ®Google Scholar
• Stanojevic S, Graham BL, Cooper BG, et al. Official ERS technical standards: global lung function initiative reference values for the carbon monoxide transfer factor for Caucasians. Eur Respir J. 2017;50(3). doi:10.1183/13993003.00711-2017.
   Web of Science ®Google Scholar
• Fletcher CM, Elmes PC, Fairbairn AS, Wood CH. The significance of respiratory symptoms and the diagnosis of chronic bronchitis in a working population. Br Med J. 1959;2(5147):257–266. doi:10.1136/bmj.2.5147.25713823475
   PubMed Web of Science ®Google Scholar
• Jones PW, Quirk FH, Baveystock CM, Littlejohns P. A self-complete measure of health status for chronic airflow limitation. The St. George’s respiratory questionnaire. Am Rev Respir Dis. 1992;145(6):1321–1327. doi:10.1164/ajrccm/145.6.13211595997
   PubMed Web of Science ®Google Scholar
• Fletcher CM. Standardised questionnaire on respiratory smyptoms: a statement prepared and approved by the MRC Committee on the Aetiology of Chronic Bronchitis (MRC breathlessness score). BMJ. 1960;2:1665.13688719
   PubMedGoogle Scholar
• Jones PW, Harding G, Berry P, Wiklund I, Chen WH, Kline Leidy N. Development and first validation of the COPD assessment test. Eur Respir J. 2009;34(3):648–654.19720809
   PubMed Web of Science ®Google Scholar
• Lang RM, Badano LP, Mor-Avi V, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 2015;16(3):233–270.25712077
   PubMed Web of Science ®Google Scholar
• Alter P, van de Sand K, Nell C, et al. Airflow limitation in COPD is associated with increased left ventricular wall stress in coincident heart failure. Respir Med. 2015;109(9):1131–1137.26231928
   PubMed Web of Science ®Google Scholar
• Ponikowski P, Voors AA, Anker SD, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37(27):2129–2200.27206819
   PubMed Web of Science ®Google Scholar
• Mathew T, Williams L, Navaratnam G, et al. Diagnosis and assessment of dilated cardiomyopathy: a guideline protocol from the British Society of Echocardiography. Echo Res Pract. 2017;4(2):G1–G13.28592613
   PubMed Web of Science ®Google Scholar
• Micallef L, Rodgers P. eulerAPE: drawing area-proportional 3-Venn diagrams using ellipses. PLoS One. 2014;9(7):e101717.25032825
   PubMed Web of Science ®Google Scholar
• Houben-Wilke S, Spruit MA, Uszko-Lencer N, et al. Echocardiographic abnormalities and their impact on health status in patients with COPD referred for pulmonary rehabilitation. Respirology. 2017;22(5):928–934.28001000
   PubMed Web of Science ®Google Scholar
• Duffy S, Marron R, Voelker H, et al. Effect of beta-blockers on exacerbation rate and lung function in chronic obstructive pulmonary disease (COPD). Respir Res. 2017;18(1):124.28629419
   PubMed Web of Science ®Google Scholar
• Kubota Y, Asai K, Furuse E, et al. Impact of beta-blocker selectivity on long-term outcomes in congestive heart failure patients with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2015;10:515–523.25784798
   PubMed Web of Science ®Google Scholar
• Suissa S, Ernst P. Beta-blockers in COPD: a methodological review of the observational studies. COPD. 2018;15(5):520–525.30822238
   PubMedGoogle Scholar
• Fisher KA, Stefan MS, Darling C, Lessard D, Goldberg RJ. Impact of COPD on the mortality and treatment of patients hospitalized with acute decompensated heart failure: the Worcester heart failure study. Chest. 2015;147(3):637–645.25188234
   PubMed Web of Science ®Google Scholar
• Barr RG, Bluemke DA, Ahmed FS, et al. Percent emphysema, airflow obstruction, and impaired left ventricular filling. N Engl J Med. 2010;362(3):217–227.20089972
   PubMed Web of Science ®Google Scholar
• Vogel-Claussen J, Schonfeld CO, Kaireit TF, et al. Effect of Indacaterol/Glycopyrronium on Pulmonary Perfusion and Ventilation in Hyperinflated Patients with Chronic Obstructive Pulmonary Disease (CLAIM). A Double-Blind, Randomized, Crossover Trial. Am J Respir Crit Care Med. 2019;199(9):1086–1096.30641027
   PubMed Web of Science ®Google Scholar
• Mesquita R, Franssen FM, Houben-Wilke S, et al. What is the impact of impaired left ventricular ejection fraction in COPD after adjusting for confounders? Int J Cardiol. 2016;225:365–370.27760413
   PubMed Web of Science ®Google Scholar
• Williams MC, Murchison JT, Edwards LD, et al. Coronary artery calcification is increased in patients with COPD and associated with increased morbidity and mortality. Thorax. 2014;69(8):718–723.24473329
   PubMed Web of Science ®Google Scholar